Antepartum testing became an important part of obstetric care during the 1970s. Beginning with the use of fetal movement recording by maternal perception and the nonstress test (NST) and contraction stress test (CST) recorded with an electronic fetal heart rate monitor, clinicians were hopeful that these tests used in a high-risk population would identify a fetus that was at increased risk of death or serious morbidity. During the past 20 years, clinicians have also used additional testing modalities, including the biophysical profile (BPP) and Doppler velocimetry and invasive procedures, like amniocentesis, chorionic villus sampling, and percutaneous umbilical blood sampling, to further evaluate the fetus thought to be at increased risk and to identify the normal fetus so that unnecessary interventions could be avoided.
Antepartum testing became an important part of obstetric care during the 1970s. Beginning with the use of fetal movement recording by maternal perception and the nonstress test (NST) and contraction stress test (CST) recorded with an electronic fetal heart rate monitor, clinicians were hopeful that these tests used in a high-risk population would identify a fetus that was at increased risk of death or serious morbidity. During the past 20 years, clinicians have also used additional testing modalities, including the biophysical profile (BPP) and Doppler velocimetry and invasive procedures, like amniocentesis, chorionic villus sampling, and percutaneous umbilical blood sampling, to further evaluate the fetus thought to be at increased risk and to identify the normal fetus so that unnecessary interventions could be avoided.
Each of these testing modalities is based on basic physiological principles that raise important questions for clinicians: How should these tests be performed? What are the parameters defining normal and abnormal? Which test or combination of tests is best for a specific obstetric high-risk condition? When should testing be initiated and with what frequency? What are the falsepositive and false-negative rates of each test? What should be the outcome expectations when these tests are used? The thoughtful and thorough chapters in this volume address these questions and help clinicians in caring for high-risk obstetric patients.
Fetal Movement
Perceived fetal motion is the simplest and least expensive technique for monitoring fetal well being in the second half of pregnancy. 1 Despite commonly held beliefs, a recent meal or juice intake is not necessary previous to testing since gross fetal body movements are not increased by rising maternal glucose levels. In addition, qualitative and quantitative measures of fetal activity do not decrease appreciably during the week previous to delivery.
Based on the assumption that a compromised fetus reduces its activity in response to decreased oxygenation, maternal perception of fetal activity can be used as a screening test for fetal well being. Documented cessation of fetal activity warns of impending death, and a gradual reduction in activity is more often associated with chronic, rather than acute, fetal compromise. Patients reporting reduced fetal activity or cessation of fetal activity should be further evaluated by other more objectively recorded antenatal tests. A NST is often the first test used in evaluating these patients. Other patients can be evaluated by use of a BPP. In either case, a reactive NST or a high score on a BPP will reassure the clinician and the patient that the perceived decreased fetal movement was a false alarm.
Fetal movement charting may reduce stillbirths. The application of this technique to low-risk pregnancies remains especially attractive because half of stillbirths occur without an obvious cause. Maternal perception of fetal movement monitoring has its greatest value when placental insufficiency is longstanding. However, its routine role in low-risk pregnancies still requires further research. Nonetheless, the presence of a vigorous fetus is reassuring and remains an attractive aspect of this type of monitoring. It is important for clinicians to keep in mind that evidence is lacking that monitoring fetal movement can be an effective independent surveillance test for predicting intrauterine growth restriction, fetal malformations, or stillbirths.
Nonstress Test
The NST has been widely accepted as a primary fetal surveillance tool for pregnancies at risk for perinatal morbidity and mortality and has also been used in combination with ultrasound observations of fetal activity and amniotic fluid volume. Its ease of application in the outpatient setting and its lack of contraindications have made it the most used and popular of the antepartum testing modalities. While randomized control trials are lacking in the evaluations of the effectiveness of the test, incorporation of the NST into high-risk antepartum protocols has been associated with an apparent reduction in intrauterine fetal death.
The generation of fetal heart rate patterns requires intact electrical conduction pathways, and those patterns that signal cellular hypoxia and acidosis include a fixed fetal heart rate baseline, loss of fetal heart rate variability and accelerations, and the ap-pearance of spontaneous late fetal heart rate decelerations. 2 For a NST to be interpreted as reactive in gestations of more than 32 weeks, a reactive tracing should contain at least two accelerations of amplitude greater than 15 beats per minute, lasting 15 seconds from beginning of the acceleration to end during a 20-minute period. Recently, a National Institutes of Child Health and Human Development (NICHD) workshop on fetal heart rate monitoring concurred that a minimal threshold for adequate accelerations before 32-week gestation can be 10 beats per minute. 3 The false-positive rate of a nonreactive NST is sufficiently high to support the need for additional testing, including a BPP or CST. A reactive NST has been associated with a prenatal mortality rate of 0.3/1000 and a perinatal death rate of 2.3/1000, confirming that adverse perinatal outcomes after a reassuring NST are uncommon. 2 Evidence to date would indicate that antepartum surveillance using the NST should not be solely relied on as an independent screening tool for complex decision making, quite similar to restrictions of maternal perception of fetal movement and umbilical Doppler velocimetry.
In most practices, the NST is used as a primary test with a nonreactive NST being followed by a CST or BPP. A positive CST or abnormal BPP suggests that the nonreactivity may be related to metabolic consequences of hypoxia, while a negative CST implies that nonreactivity has occurred for some other reason, like fetal sleep.
External stimulation of the fetus has been applied as an additional parameter of fetal well-being testing. Observational and randomized controlled trials have shown that fetal vibroacoustic stimulation significantly shortens NST time, and reduces the likelihood of a nonreactive NST. 4 In addition, an acceleratory fetal heart rate response intrapartum, by manual manipulation, digital scalp stimulation, or with vibroacoustic stimulation, significantly reduces the likelihood of fetal acidosis.
In almost all studies of intrapartum fetal stimulation testing, an acceleratory fetal heart rate response precluded a scalp pH less than 7.20 and a diagnosis of metabolic acidosis. However, absence of an acceleratory fetal heart rate response to stimulation in labor correctly identifies fetuses with a pH of less than 7.25 in only 50% of the cases. 4
Contraction Stress Test
Contraction stress testing is based on the concept that a fetus beginning to develop marginal basal oxygenation will, with the ordinary hypoxemic stress of uterine contractions, manifest late decelerations. 5 The fetus with a reasonable reserve of uteroplacental function will not display late decelerations unless the test is conducted in such a way as to significantly reduce uterine blood flow (eg, hyperstimulation). The test can be performed by use of intravenous oxytocin using the amount necessary to achieve adequate uterine activity but can also be performed with nipple stimulation, thereby reducing testing time. 5 Contraction stress test interpretations are negative, positive, or equivocal, with this last category having three subgroups of suspicious, hyperstimulation, and unsatisfactory. A negative CST exhibits no late decelerations with a contraction frequency of three per 10 minutes. Reactivity of the fetal heart rate is usually present but is not necessary for a negative interpretation. A negative CST interpretation is noted in approximately 80% to 90% of tests and, in the absence of clinical deterioration, need be repeated only weekly. 5 A positive CST reveals late decelerations occurring with one half or more of the uterine contractions. If uterine contractions are infrequent, but are consistently followed by a late deceleration, then it is not necessary to further stress the fetus.
Clinically, it has been noted that a positive CST associated with a nonreactive fetal heart rate baseline usually precludes a successful trial of labor, thus indicating a need for a cesarean delivery. Alternatively, a positive CST with normal fetal heart rate re-activity indicates that labor conducted with uterine resuscitative measures may be tolerated. 5 An equivocal CST is observed in approximately 10% of tests performed. As a group, equivocal results impart no useful clinical information and testing should usually be repeated within 24 hours. A suspicious CST has at least one late deceleration, while hyperstimulation implies that late decelerations occurred because of the abnormally increased uterine activity. An unsatisfactory CST is usually noted in obese patients whose body habitus impairs external fetal heart rate monitoring.
When should testing be started and how often should it be performed? The initiation of antepartum testing depends on an institution's ability to care for the very preterm newborn. At most centers with neonatal intensive care units this gestational age threshold is approximately 24 weeks. 5 In a study of 3540 pregnancies in which over 1200 CSTs were performed with a negative test result repeated on a weekly basis, there were no antepartum deaths of normally formed fetuses (false-negative rate corrected for lethal anomalies zero), supporting the premise that the CST can be performed only once a week, precluding deterioration of maternal condition like diabetic ketoacidosis. In contrast, the NST should be done twice weekly. 6 While the CST and NST are excellent antepartum tests, the CST is perhaps a better long-range predictor of uteroplacental deterioration. 5 A problem with the NST as a primary test is the 15% to 30% rate of nonreactive test results, the majority of which are unrelated to fetal pathology but requires further evaluation. A persistently nonreactive NST, followed by a positive CST, suggests serious fetal compromise. 5 Retrospectively, that same fetus might have been served better by having had serial CSTs.
It would seem reasonable that in considering which of these two tests should be used first, the CST should be reserved for pregnancies considered to have the highest risk conditions, like hypertension, type 1 and type 2 diabetes mellitus, and intrauterine growth restriction, while the NST be applied in the remainder of high-risk gestations like those with decreased fetal movement. Considering that the nipple stimulation method of contraction stress testing takes only slightly more time than the NST and could be used only once a week, one could reasonably liberalize the indications for the CST.
Biophysical Profile
The BPP score, an ultrasound-based test used in combination with the NST, evaluates the probability of a fetus having sufficient delivery of oxygen to select primary and secondary target organs, including the brain, kidney, and fetal lung, to maintain normal function. The underlying operating principle is the concept that tissue hypoxia will result in suppression or loss of normal function. 7 Fetal breathing movements, a normal biophysical event in fetal life arising from signals generated by the respiratory center is located in the region of the low midbrain. Fetal breathing movements cease abruptly when tissue PO2 falls by about 8 to 10 torr. Therefore, a fetus with tissue hypoxemia will not exhibit normal breathing movements. It must be kept in mind, however, that factors other than hypoxemia, like a change in fetal state can decrease an activity. In fact, this is usually the explanation for absence of fetal breathing.
The BPP includes an assessment of amniotic fluid volume, a reflection of fetal urine production and chronic fetal state. During times of fetal stress, blood flow to the heart and brain increases, whereas blood flow to most other organs, including the kidney, declines. Fetal urine production falls in the presence of hypoxemia and acidemia and may totally cease with asphyxia. The average time for a fetus to progress from normal to abnormal fluid levels during times of increasing fetal stress is approximately 15 days, and to reach severe oligohydramnios is approximately 23 days, making amniotic fluid volume assessment an obvious fetal sign of chronic hypoxemia and acidemia.
It is this response to fetal stress that has resulted in amniotic fluid volume assessment becoming an important addition to antepartum testing. Amniotic fluid volume studies have become the standard of care in managing at risk pregnancies especially with its addition to the BPP scoring system. Regardless of which method is used to evaluate the amount of amniotic fluid present in an at risk pregnancy, studies reveal a close relationship between low levels of fluid and adverse fetal outcome.
The four-quadrant amniotic fluid index (AFI) is currently the most widely used method for evaluating amniotic fluid status in single pregnancies and the one most likely to reflect actual volume. Studies have demonstrated that antepartum AFI values less than or equal to 5 cm are associated with an increased risk of cesarean delivery and an increase in perinatal morbidity and mortality when compared with a group with an AFI greater than or equal to 5 cm. 8 The BPP scoring system is different from other antepartum testing in that it combines measurements of acute biophysical variables, like fetal breathing, fetal heart rate accelerations, and gross body movements, that reflect immediate fetal condition along with amniotic fluid volume, a variable that reflects a more chronic fetal condition.
The BPP score, when normal (a score of 8 or 10), is a reliable and accurate measure of normal fetal tissue oxygenation, whereas an abnormal score (less than or equal to 6 of 10) heightens the probability of tissue hypoxia. In a database of almost 1300 paired observations, a normal BPP score was never associated with an abnormal fetal pH. However, there is less conformity regarding the predictive accuracy of an abnormal BPP score. At the other end of the spectrum, the most abnormal BPP score of 0/10 is almost always indicative of fetal compromise. The BPP scores between the normal and most abnormal score demand further testing and consideration of clinical factors in making short-or long-range plans for the pregnant patient.
The purpose of antepartum testing is identification of the fetus at risk for death or serious morbidity and delivery of the patient by the safest route, so as to prevent a less than optimal outcome. Clinical analysis of stillborn infants indicates that at least 70% of these fetuses have evidence of intrauterine growth restriction. Of pregnancies ending in stillbirth, 90% or more have clinical signs of chronic compromise. This implies that in many high-risk pregnancies there will be signs of impending problems and that these signs could be noted before intrauterine fetal death occurs.
Data on the BPP supports the conclusion that management based on a BPP scoring system has a significant impact on stillbirth rates and has an effect on neonatal mortality rates. According to one large study of 26,257 patients, the fetal death rate within a week of a normal BPP was 0.7/1000. The study also found that the NST did not improve the diagnostic accuracy over the ultrasound parameters. This low false-negative rate makes the BPP an extremely useful antepartum fetal testing modality especially early in the third trimester.
Doppler Velocimetry
Doppler ultrasound is a noninvasive technique that is commonly used to evaluate maternal and fetal hemodynamics based on the premise that an insufficient uterine, placental, or fetal circulation results in adverse pregnancy outcome and that these abnormalities can be defined with Doppler velocimetry. 9 Despite the fact that Doppler velocimetry is the newest of the antepartum testing modalities, it has been the subject of more randomized control trials than any other tests of fetal well being. Of all Doppler evaluatory studies of the fetus, umbilical artery Doppler velocimetry seems to correlate best with fetal outcome. Umbilical artery Doppler velocimetry testing is based on the physiological principle that, because of de-creasing placental impedance with gestational age, systolic to diastolic ratios in a normal pregnancy decrease with the progression of gestational age.
There is no consistent agreement as to what constitutes an abnormal umbilical Doppler study, with most investigators using a systolic to diastolic ratio greater than 3 to indicate an abnormal test beyond the 30week gestation period. Evidence from clinical experience and randomized control trials shows a significant association between abnormal umbilical artery Doppler velocimetry and adverse perinatal outcome. 9 In particular, several investigators have reported on the association of an abnormal umbilical artery velocity waveforms with intrauterine fetal growth restriction.
While umbilical artery Doppler velocimetry studies are not recommended as an independent antepartum testing modality, it can be extremely useful in differentiating the growth restricted fetus from a constitutionally small fetus. Studies suggest that additional antenatal surveillance is unnecessary in fetuses with suspected growth restriction when the umbilical artery Doppler study is normal. Small fetuses with normal umbilical artery Doppler studies are more likely to be constitutionally small and healthy rather than growth restricted and sick. 9 At the other end of the spectrum, numerous randomized trials have shown that abnormal umbilical artery velocity waveforms are helpful in identifying a growthrestricted fetus at risk for a poor outcome.
It seems clear that since a growthrestricted fetus with abnormal umbilical artery Doppler velocimetry is more likely to suffer an adverse perinatal outcome, a clinician faced with these findings should institute monitoring with a NST, CST or BPP, and serial umbilical Doppler studies.
As pregnancy advances to a stage when there is a reasonable chance for neonatal survival, around 24 weeks, antepartum fetal testing to assess fetal well-being may be initiated. For high-risk and low-risk pregnancies, maternal perception of fetal activity can be a simple and inexpensive means for patients to alert physicians to possible fetal problems. While false-positive rates are quite high, patients have occasionally presented themselves early in the course of fetal compromise allowing for lifesaving interventions.
With the high-risk pregnancy, other more objective testing modalities should be used. The most popular of these tests are the NST and BPP. Both are associated with low stillbirth rates in the presence of a normal test. The CST is still considered the criterion standard of antepartum testing since it, unlike any of the other testing modalities, evaluates the fetus while undergoing the stress of contractions. A fetus may have the metabolic reserves to register a reactive NST or a high score on a BPP, yet display late decelerations while undergoing a CST. This information may be quite useful in early identification of fetal compromise. The relative simplicity of the nipple stimulation test may make the CST more desirable to patients and physicians and could be used as a first line screening test instead of the more commonly used NST and BPP.
The addition of AFI to the BPP or the NST has gained considerable popularity. As a sign of renal function, this test can be viewed as an indicator of chronic fetal compromise when oligohydaminos is present. However, as with umbilical Doppler velocimetry, which has its largest role in the evaluation of the growth restricted fetus, AFI cannot be used as an independent testing modality. Both need to be put into proper context along with results of the NST, BPP, CST and the overall clinical situation.
Antepartum testing is a valuable tool for physicians caring for the pregnant patient. It is essential that physicians, understand the physiological basis, indications, contraindications, methodology, interpretation, and predictive value of each test. Of all the antepartum testing modalities described in this chapter, none can be described as the best one to use. Each test has certain pros and cons that need to be carefully evaluated in the clinical context in which it is used.
